Menu
Back to Journals » Clinical Ophthalmology » Volume 10
Update and clinical utility of the LenSx femtosecond laser in cataract surgery
Authors Roberts TV, Lawless M, Sutton G, Hodge C
Received 11 July 2016
Accepted for publication 1 September 2016
Published 17 October 2016 Volume 2016:10 Pages 2021—2029
DOI https://doi.org/10.2147/OPTH.S94306
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Timothy V Roberts,1,2 Michael Lawless,1,2 Gerard Sutton,1,2 Chris Hodge1,3
1Vision Eye Institute, Chatswood, 2Sydney Medical School, University of Sydney, 3Graduate School of Health Sciences, University of Technology, Sydney, NSW, Australia
Abstract: The introduction of femtosecond lasers to cataract surgery has been the major disruptive technology introduced into ophthalmic surgery in the last decade. Femtosecond laser cataract surgery (FLACS) integrates high-resolution anterior segment imaging with a femtosecond laser allowing key steps of cataract surgery to be performed with computer-guided laser accuracy, precision, and reproducibility. Since the introduction of FLACS, there have been significant advances in laser software and hardware as well as surgeon experience, with over 250 articles published in the peer-reviewed literature. This review examines the published evidence relating to the LenSx platform and discusses surgical techniques, indications, safety, and clinical results.
Keywords: femtosecond laser, cataract surgery, LenSx, IOL
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.